The secondary analysis of the TRAILBLAZER-ALZ and TRAILBLAZER-ALZ 2 clinical trials revealed that amyloid-related imaging abnormalities (ARIA) were more prevalent in patients with early symptomatic Alzheimer disease receiving donanemab compared to placebo. ARIA is an adverse event associated with donanemab treatment, requiring safety monitoring. The study identified six independent baseline risk factors for ARIA-E and highlighted the importance of early monitoring through MRI scans to enhance safety.

Source: JAMA Neurology